Floatz logo

Esomeprazole

Gastrointestinal Stromal Tumors

Erasmus Medical CenterSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Gastrointestinal Stromal Tumors cohort.

Asset / SponsorPhaseRating
MIDAZOLAM
Blueprint Medicines Corporation
Phase 4BBB
Regorafenib
Institut Bergonié
Phase 4BBB
Imatinib
M.D. Anderson Cancer Center
Phase 2BB
CAFFEINE
Markus Joerger
Phase 4BB
Nilotinib
Novartis Pharmaceuticals
Phase 4BB

View all 50 →

Same molecule, other indications

Esomeprazole is also rated in:

relapsing-remitting multiple sclerosisDormant
BB
Indicative ·
68 / 100
View asset →
morbid obesityDormant
B
Indicative ·
62 / 100
View asset →
colorectal neoplasmDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →